Jingsong Zhang, MD, PhD

Where You Are:
Jingsong Zhang, MD, PhD

Assistant Member

Office  (813) 745-8418

Education And Training
  • Fellow, University of Michigan Comprehensive Cancer Center, 2010 - Hematology-Oncology
  • Intern/Resident, New York Downtown Hospital, 2007 - Internal Medicine
  • Rotations, Memorial Sloan Kettering Cancer Center, 2007 - Medical Oncology
  • PhD, University of Southern California, 2001 - Pathology
  • MD, Peking Union Medical College, 1996


Dr. Zhang’s research focuses on 1) defining and characterizing deregulated pathways with therapeutic relevance in subsets of human cancers, and 2) developing and implementing biomarker-driven therapeutics into patient-based therapeutic trials.He aims to identify the DNA damage repair pathways that metastatic prostate cancers rely on and then assess the therapeutic potential of targeting these pathways. Preliminary data indicates that blocking key proteins in DDR pathways with PARP inhibitor, DNA-PK inhibitor or BRCA1 shRNA sensitized metastatic prostate cancer cells to DNA damaging chemotherapy drugs. The synergistic combinations are being tested in metastatic prostate cancer mouse models.Secondly, Dr. Zhang is evaluating r-H2AX as a prognostic or predictive marker.Unrepaired DNA single strand breaks will be converted to double strand breaks (DSB) during DNA replication, and r-H2AX is a well-known marker for DNA DSB.  High levels of r-H2AX expression in prostate cancers would correlate with diminished DNA repair pathways and therefore high mutation rates.  Dr. Zhang and colleagues will develop a scoring system for r-H2AX expression by immunohistochemistry and correlate that with patients’ clinical outcomes. Based on initial results, the value of r-H2AX can be further evaluated in larger patient cohorts with multi-variant analysis.  Assays also can be developed to detect r-H2AX in circulating tumor cells.

  • Wu M, Wang X, McGregor N, Pienta K, Zhang J. Dynamic Regulation of Rad51 by E2F1 and p53 in Prostate Cancer Cells upon DrugInduced DNA Damage under Hypoxia. Mol Pharmacol. 2014 Mar. Pubmedid: 24627085.
  • Zhang J. Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer. Asian J Androl. 2014 Feb. Pubmedid: 24589464.
  • Liu JJ, Zhang J. Sequencing systemic therapies in metastatic castration-resistant prostate cancer. Cancer Control. 2013 Jul;20(3):181-187. Pubmedid: 23811702.
  • Song Y, Lucas M, Alcaraz M, Zhang J, Brazier C. Ultraviolet photodissociation dynamics of the phenyl radical. J Chem Phys. 2012 Jan;136(4):044308. Pubmedid: 22299872.
  • Zhang J, Lee J, Urba S, Foster J, Worden F. A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers. Cancer Invest. 2010 Nov;28(9):910-916. Pubmedid: 20590443.
  • Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Ng T, Reynolds CP, Triche TJ, Sorensen PH. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res. 2007 Apr;67(7):3094-3105. Pubmedid: 17409416. Pmcid: PMC3906735.
  • Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res. 2005 Jun;65(11):4633-4644. Pubmedid: 15930281.
  • Zhang J, Hu S, Schofield DE, Sorensen PH, Triche TJ. Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas. Cancer Res. 2004 Sep;64(17):6026-6034. Pubmedid: 15342383.
  • Hobbs JA, Cho S, Roberts TJ, Sriram V, Zhang J, Xu M, Brutkiewicz RR. Selective loss of natural killer T cells by apoptosis following infection with lymphocytic choriomeningitis virus. J Virol. 2001 Nov;75(22):10746-10754. Pubmedid: 11602716. Pmcid: PMC114656.
  • Tsao JL, Zhang J, Salovaara R, Li ZH, Järvinen HJ, Mecklin JP, Aaltonen LA, Shibata D. Tracing cell fates in human colorectal tumors from somatic microsatellite mutations: evidence of adenomas with stem cell architecture. Am J Pathol. 1998 Oct;153(4):1189-1200. Pubmedid: 9777950. Pmcid: PMC1853055.
  • Henderson-Jackson E, Sexton W, Zhang J, Hakam A, Petrovskyy VS, Bui MM, Chuang ST. Cystic prostatic ductal adenocarcinoma: an unusual presentation and cytological diagnosis. Ann Clin Lab Sci. 2012 Winter;42(1):81-88. Pubmedid: 22371914.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions